This trial is evaluating whether BNT162b2 will improve 18 primary outcomes and 7 secondary outcomes in patients with Respiration Disorders. Measurement will happen over the course of up to 7 days after each dose.
This trial requires 1655 total participants across 11 different treatment groups
This trial involves 11 different treatments. BNT162b2 is the primary treatment being studied. Participants will be divided into 11 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Given the current coronavirus outbreak, we discuss here the relevance of coronavirus to the public health of the world, and the urgency to use appropriate communication methods. Our present review further examines the viral transmission characteristics of the SARS-CoV-2 virus, which shed light on the pathogenesis of the viral disease epidemic." - Anonymous Online Contributor
"There is no currently available evidence suggesting that people with a recent history of or current COVID-19 infection are more likely to develop symptoms of COVID-19, to develop severe or life-threatening complications of COVID-19, or to be hospitalized with COVID-19. A small subset of adults may experience transient or asymptomatic infection; individuals who develop acute symptoms of COVID-19 should receive adequate follow-up as usual. There was an asymptomatic but substantial proportion of reported COVID-19 infections among healthy adults who were neither required to treat or evaluated." - Anonymous Online Contributor
"Patients with COVID-19 present with symptoms or signs which can be suggestive of any of the illnesses they have had contact with previously, including: fever, cough, muscle pain, fatigue and myalgia, headache, vomiting, diarrhea, pneumonia, and abdominal pain and tenderness or bloating. There is a high rate of coexisting illnesses which should be considered in diagnosing patients with confirmed COVID-19 or suspicion of COVID-19 infections." - Anonymous Online Contributor
"Covid-19 can be cured. In light of the ongoing coronavirus outbreak, a new type of infectious disease might be encountered, and a disease-sorting strategy might be necessary, if we could eradicate it from the human population by vaccines or drugs." - Anonymous Online Contributor
"Findings from a recent study demonstrated that the prevalence of cough has significantly increased in the outpatient department during the 2019-20 coronavirus epidemic, and the most commonly prescribed medications were Oseltamivir, Paracetamol, and Ipratropium." - Anonymous Online Contributor
"Many animals, including cattle, camels, wild and domestic animals, wild and domesticated pigs, waterfowls, monkeys, bats and some other animals are susceptible to the disease. Other than human infections (e.g. direct droplet or close contact transmission), the virus can also be transmitted between humans through direct contact with any of the previously infected mammals and it has the potential to spread from human to human in a manner similar to HIV/AIDS.\n\n- "
"Erythranol palmitate\n\nErythranol palmitate is a member of the stanol series of carotenoids." - Anonymous Online Contributor
"Results from a recent clinical trial show for the first time an overall superiority against a placebo group of the investigational drug bnt162b2 in comparison to current standard care. Both studies underscore the potential for a low toxicity safety profile and highlight the importance of patient selection based on clinical manifestations." - Anonymous Online Contributor
"(a) The H7N9 epidemic began at the end of January 2019 when the Ministry of Health advised travelers to the Hubei Province and started quarantining those coming from Hubei within 4 days, and (b) as of 28 December, more than 10 years after it became human, it has turned out to be the primary cause of this epidemic among human beings, with the Hubei virus being the main one in the primary human-to-human transmissions." - Anonymous Online Contributor
"Bnt162b2 was well tolerated and safe when administered across multiple dosages by intravenous, intramuscular, or subcutaneous routes, and no evidence of pharmacokinetic interaction or safety concern was observed for the Bnt162b2 drug." - Anonymous Online Contributor
"Based on the numbers reported in the literature, approximately 1 in 4 of those who develop symptomatic infection will have a fatal outcome. Given the complexity of diagnosing the disease, and the fact that many infected people are asymptomatic, it is possible that this number is an underestimate, indicating the possible seriousness of the disease. At this time, there is no evidence that it is more likely to become serious in those with other underlying diseases. More work is urgently required to find effective treatments and to improve diagnostics." - Anonymous Online Contributor
"The bnRNA bnt162b2 is a novel and efficacious anti-HCV agent which has the potential to offer a novel therapeutic lead and a new therapeutic strategy for HCV infection." - Anonymous Online Contributor
"Most patients and medical providers will not pursue a clinical trial for the coronavirus, and even those who would consider it will be slow to consider it. Thus, clinical trials may not be the answer, and clinical trial participation should be made widely available in all settings to ensure equitable access for those who want to participate." - Anonymous Online Contributor